Business
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5
About this update from Novartis Ag
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1Vanrafia reduced protein in urine by 38.3% vs placebo at 9 months, with reductions sustained through end of treatment1,2Patients additionally receiving background SGLT2 inhibitors also consistently showed slower kidney function decline with Vanrafia vs placebo1,2Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia® (atrasentan) versus placebo in adults with IgA nephropathy (IgAN)1,2. Results were published in The Lancet and presented at the European Renal Association (ERA) Congress.Estimated glomerular filtration rate (eGFR) change from baseline favored Vanrafia, alongside sustained reductions of protein in the urine through end of treatment. Benefits were consistent across different measures of kidney function and in patients additionally receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors1,2.“These results provide robust evidence of clinically meaningful slowing of kidney function decline over more than two years of treatment, reinforcing findings from the earlier analysis of proteinuria reduction,” said Richard Lafayette, MD, FACP, Professor of Medicine, Nephrology, Director of the Glomerular Disease Center at Stanford University Medical Center, and ALIGN Study Investigator and Steering Committee Member. “They highlight the role of a highly selective endothelin A receptor antagonist as part of an evolving treatment approach for IgAN.”Key efficacy results1,2 Endpoint Vanrafia Placebo Effect vs placeboMain cohort Change from baseline in eGFR at end of study* (Week 136) -7.5 -9.9 2.4 (p=0.057) Change from baseline in eGFR at end of treatment (Week 132) -6.9 -9.5 2.6 (p=0.039) Annualized total eGFR slope (Weeks 0-136) -2.7 -4.1 1.4 (~34% slower decline; p=0.003) Change from baseline in urine protein-to-creatinine ratio (UPCR) at 9 months (Week 36)† -39.5% -1.9% 38.3% relative reduction Change from baseline in UPCR at end of treatment (Week 132) † -28.8% -0.6% 28.4% relative reduction SGLT2 inhibitor cohort Change from baseline in eGFR at end of study* (Week 136) -1.5 -10.6 9.1 (p=0.004) * Week 132 plus a 4-week off-treatment follow-up† UPCR at Week 36 assessed using 24-hour urine collection; UPCR at Week 132 assessed...